Osteoporosis

Clinics in Geriatric Medicine

Volumn 21, Issue 3 SPEC. ISS., 2005, Pages 603-629

  Simon, Lee S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANDROGEN; ANTICONVULSIVE AGENT; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYTOKINE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; HEPARIN; IBANDRONIC ACID; INTERLEUKIN 1; METHOTREXATE; NANDROLONE; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STANOZOLOL; STRONTIUM RANELATE; TESTOSTERONE; TILUDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ACUTE HEART INFARCTION; AGING; BONE BIOPSY; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE RADIOGRAPHY; BONE TURNOVER; CALCIUM ABSORPTION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS DISEASE; FLUSHING; FRACTURE; HEADACHE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTENSION; LABORATORY TEST; LIPID BLOOD LEVEL; LIVER TOXICITY; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSICAL EXAMINATION; POSTMENOPAUSE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; STROKE; VENOUS THROMBOEMBOLISM;

EID: 19344364440     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2005.02.002     Document Type: Review

References (236)

1. G.A. Rodan Introduction to bone biology Bone 13 1992 S3
2. P.G. Robey The biochemistry of bone Endocrinol Metab Clin North Am 18 1989 859
3. D. Heinegard, K. Hultenby, and A. Oldberg Macromolecules in bone matrix Connect Tissue Res 21 1989 3
4. P. Bork The modular architecture of vertebrate collagens FEBS Lett 307 1992 49
5. S.M. Krane, and L.S. Simon Organic matrix defects in metabolic and related bone diseases A. Veis The chemistry and biology of mineralized connective tissues 1981 Elsevier Science New York 185
6. Brown J.P., Delmas P.D., Malaval L., et al. Serum bone GLA-protein: a specific marker of bone formation in postmenopausal osteoporosis. In Proceedings of the Copenhagen International Symposium on Osteoporosis. Department of Clinical Chemistry, Glostrop Hospital, Denmark; 1984
7. J.B. Lian, M. Coutts, and E. Canalis Studies of hormonal regulation of osteocalcin synthesis in cultured fetal rat calvariae J Biol Chem 260 1985 8706
8. 2HS- glycoprotein Calcif Tissue Res 22 1976 27
9. 2HS-glycoprotein concentrations in Paget's disease of bone: its possible significance Clin Sci 58 1980 435
10. A. Franzen, and D. Heinegard Isolation and characterization of two sialoproteins present only in bone calcified matrix Biochem J 232 1985 715
11. E.H. Sage, and P. Bornstein Extracellular proteins that modulate cell-matrix interactions, SPARC, tenascin, and thrombospondin J Biol Chem 266 1991 14831
12. R. Baron Polarity and membrane transport in osteoclasts Connect Tissue Res 20 1988 109
13. T. Suda, N. Takahashi, and T.J. Martin Modulation of osteoclast differentiation Endocr Rev 13 1992 66
14. J.E. Aubin Osteoclast adhesion and resorption: the role of podosomes J Bone Miner Res 7 1992 365
15. H.C. Blair, S.L. Teitelbaum, and R. Ghiselli Osteoclast bone resorption by a polarized vacuolar proton pump Science 245 1989 855
16. + ATPases Proc Natl Acad Sci USA 89 1992 6257
17. S.J. Jones, N.M. Hogg, and I.M. Shapiro Cells with Fc receptors in the cell layer next to osteoblasts and osteoclasts in bone Metab Bone Dis Relat Res 2 1981 357
18. E. Canalis, T.L. McCarthy, and M. Centrella Growth factors and cytokines in bone cell metabolism Annu Rev Med 42 1991 17
19. E.M. Gravallese, D.L. Galson, S.R. Goldring, and P.E. Auron The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption Arthritis Res 3 2001 6 12
20. R.L. Jilka, G. Hangoc, and G. Girasole Increased osteoclast development after estrogen loss: mediation by interleukin-6 Science 257 1992 88
21. G.D. Roodman, N. Kurihara, and Y. Ohsaki Interleukin 6: a potential autocrine/paracrine factor in Paget's disease of bone J Clin Invest 89 1992 46
22. 3-induced osteoclast development J Bone Miner Res 7 1992 S110
23. L.G. Raisz, and B.E. Kream Regulation of bone formation N Engl J Med 309 1983 29
24. A.M. Parfitt Surface specific bone remodeling in health and disease M. Kleerekopper S.M. Krane Clinical disorders of bone and mineral metabolism 1989 Mary Ann Liebert New York 7
25. T.J. Chambers, P.M.J. McSheehy, and B.M. Thomson The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones Endocrinology 60 1985 234
26. G.R. Mundy, J.L. Shapiro, and J.G. Bandelin Direct stimulation of bone resorption by thyroid hormones J Clin Invest 58 1976 529
27. T.L. McCarthy, M. Centrella, and E. Canalis Regulatory effects on insulin-like growth factor I and II on bone collagen synthesis in rat calvarial cultures Endocrinology 124 1989 301
28. J.M. Hock, and J. Fonseca Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone Endocrinology 127 1990 1804
29. H. Lin, T.L. Harris, and M.S. Flannery Expression cloning of an adenylate cyclase-coupled calcitonin receptor Science 254 1991 1022
30. A. Gorn, H.Y. Lin, and M. Yamin Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line J Clin Invest 90 1992 1726
31. L.C. Johnson The kinetics of skeletal remodeling. A further consideration of the theoretical biology of bone Birth Defects 2 1966 66
32. H.M. Frost Bone remodeling and its relationship to metabolic bone diseases 1973 Charles C. Thomas Springfield (IL)
33. A.M. Parfitt The coupling of bone formation: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis Metab Bone Dis Relat Res 4 1982 1
34. Parfitt A.M., Kleerehoper M. Diagnostic value of bone histomorphometry and comparison on histologic measurements and biochemical indices of bone remodeling. In: Christiansen C., Arnaud C.D., Nordin B.E.C., et al, editors. Proceedings of the Copenhagen International Symposium on Osteoporosis, Aalborg Stiftsbogtrykkeri, Denmark, 1984. p. 111
35. B.L. Riggs, and L.J. Melton III Involutional osteoporosis N Engl J Med 314 1986 1676
36. B.L. Riggs, and L.J. Melton III Evidence for two distinct syndromes of involutional osteoporosis Am J Med 75 1983 899
37. L.J. Melton III, and B.L. Riggs Further characterization of the heterogeneity of the osteoporotic syndromes M. Kleerekoper S.M. Krane Clinical disorders of bone and mineral metabolism 1989 Mary Ann Liebert New York 145
38. R. Marcus, J. Kosek, and A. Pfefferbaum Age-related loss of trabecular bone in premenopausal women. A biopsy study Calcif Tissue Int 35 1983 406
39. L.V. Avioli, and R. Lindsay The female osteoporotic syndrome(s) L.V. Avioli S.M. Krane Metabolic bone disease and clinical related disorders 1990 W.B. Saunders Philadelphia 397
40. C. Nagant de Deuxchaisnes The pathogenesis and treatment of involutional osteoporosis A.S.t.J. Dixon R.G.G. Russell T.C.B. Stamp Osteoporosis, a multi-disciplinary problem. Royal Society of Medicine International Congress and Symposium Series No. 55 1983 Academic Press London 291
41. A.M. Parfitt, M.-S. Shih, and D.S. Rao Relationship between bone formation rate and osteoblast surface in aging and osteoporosis: evidence for impaired osteoblast recruitment in pathogenesis J Bone Miner Res 7 Suppl 1 1992 S116
42. B.L. Riggs, and L.J. Melton The prevention and treatment of osteoporosis N Engl J Med 327 1992 620
43. A.M. Parfitt Bone remodeling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures B.L. Riggs L.J. Melton III Osteoporosis: etiology, diagnosis, and management 1988 Raven Press New York 45
44. A.M. Parfitt, C.H.E. Mathews, and A.R. Villanueva Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: implications for the microanatomic and cellular mechanisms of bone loss J Clin Invest 72 1983 1396
45. B.P. Lukert, and L.G. Raisz Glucocorticoid-induced osteoporosis: pathogenesis and management Ann Intern Med 112 1990 352 364
46. C.M. Stavros, and R.L. Jilka Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis N Engl J Med 332 1995 305 311
47. M.C. Hurwitz Cytokines and estrogen in bone: anti-osteoporotic effects Science 260 1993 623
48. S.R. Cummings, and M.C. Nevitt Risk factors for hip fracture in white women N Engl J Med 332 1995 767 773
49. D.C. Bauer, W.S. Browner, and J.A. Cauley Factors associated with appendicular bone mass in older women Ann Int Med 118 1993 657 665
50. R.L. Prince, M. Smith, and I.M. Dick Prevention of postmenopausal osteoporosis N Engl J Med 325 1991 1189
51. R. Pacifici Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 50 1992 295
52. R.L. Jilka, G. Hangoc, and G. Girasole Increased osteoclast development after estrogen loss: mediation of interleukin-6 Science 257 1992 88
53. G. Girasole, R.L. Jilka, and G. Passeri 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens J Clin Invest 89 1992 883
54. L.R. Chaudhary, T.C. Spelsberg, and B.L. Riggs Production of various cytokines by normal human osteoblast-like cells in response to interleukin-1β and tumor necrosis factor-α: lack of regulation by 17β-Estradiol Endocrinology 130 1992 2528
55. D. Rickard, G. Russel, and M. Gowen Oestradriol inhibits the release of tumor necrosis factor but not interleukin 6 from adult human osteoblasts in vitro Osteoporos Int 2 1992 94
56. P.E. Keeting, L. Rifas, and S.A. Harris Evidence for interleukin-1β production by cultured normal human osteoblast-like cells J Bone Miner Res 6 1991 827
57. M.J. Oursler, C. Cortese, and P. Keeting Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone Endocrinology 129 1991 3313
58. G. Mbalaviele, P. Orcel, and Z. Bouizar Transforming growth factor-β enhances calcitonin-induced cyclic AMP production and the number of calcitonin receptors in long-term cultures of human umbilical cord blood monocytes in the presence of 1,25- dihydroxycholecalciferol J Cell Physiol 152 1992 486
59. H.G. Schneider, V.P. Michelangeli, and R.J. Frampton Transforming growth factor-β modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells Endocrinology 131 1992 1383
60. V. Knappe, F. Raue, and J. Pfeilschifter Tumor necrosis factor-alpha inhibits the stimulatory effect of the parathyroid hormone-related protein on cyclic AMP formation in osteoblast-like cells via protein kinase-C + blind E Biochem Biophys Res Commun 182 1992 341
61. N. Takahashi, N. Udagawa, and T. Akatsu Role of colony-stimulating factors in osteoclast development J Bone Miner Res 6 1991 977
62. L.J. Melton, S.R. Cummings, and C.C. Johnston Heterogeneity of age-related fractures: implications for epidemiology Bone Miner 2 1987 321
63. J.C. Stevenson, C.J. Hillyard, and I. MacIntyre A physiological role for calcitonin: protection of the maternal skeleton Lancet 2 1979 769
64. L.J. Deftos, M.H. Weissman, and G.W. Williams Influence of age and sex on plasma calcitonin in human beings N Engl J Med 302 1980 1351
65. H.M. Taggart, C.H. Chestnut III, and J.L. Ivey Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis? Lancet 1 1982 475
66. R.D. Tiegs, J.J. Body, and J.M. Barta Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage J Bone Miner Res 1 1986 339
67. L.J. Melton, H.W. Wahner, and L.S. Richelson Osteoporosis and the risk of hip fracture Am J Epidemiol 124 1986 154
68. M.P. Whyte, M.A. Bergfeld, and W.A. Murphy Postmenopausal osteoporosis: a heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients Am J Med 72 1982 193
69. S.R. Cummings, S.M. Rubin, and D. Black The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen Clin Orthop 252 1990 163
70. J.S. Finklestein, R.M. Neer, and B.M.K. Biller Osteopenia in men with a history of delayed puberty N Engl J Med 326 1992 600
71. J.C. Prior, Y.M. Vigna, and M.T. Schechter Spinal bone loss and ovulatory disturbances N Engl J Med 323 1990 1221
72. A. Klibanski, R.M. Neer, and I.Z. Beitins Decreased bone density in hyperprolactinemic women N Engl J Med 303 1980 1511
73. D. Hartwell, B.J. Riis, and C. Christiansen Changes in vitamin D metabolism during natural and medical menopause J Clin Endocrinol Metab 71 1990 127
74. D.T. Villareal, R. Civitelli, and A. Chines Subclinical vitamin D deficiency in post- menopausal. Women with low vertebral bone mass J Clin Endocrinol Metab 72 1992 628
75. J.C. Gallagher, B.L. Riggs, and J. Eisman Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium J Clin Invest 64 1979 729
76. D.M. Slovik, J.S. Adams, and R.M. Neer Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients N Engl J Med 305 1981 372
77. B.L. Riggs, A. Hamstra, and H.F. DeLuca Assessment of 25-hydroxyvitamin D 1α-hydroxylase reserve in postmenopausal osteoporosis by administration of parathyroid extract J Clin Endocrinol Metab 53 1981 833
78. J.A. Kanis, and F.A. Pitt Epidemiology of osteoporosis Bone 13 Suppl 1992 7
79. R. Armamonto-Villareal, D.T. Villareal, and L.V. Avioli Estrogen status and hereditary are major determinants of premenopausal bone mass J Clin Invest 90 1992 2464
80. S.R. Cummings Are patients with hip fractures more osteoporotic? Review of the evidence Am J Med 78 1985 487
81. C.C. Johnston, and C.W. Slemenda Risk prediction of osteoporosis: a theoretic overview Am J Med 91 Suppl 5B 1991 47
82. J.L. Kelsey, W.S. Browner, and D.G. Seeley Risk factors for fractures of the distal forearm and proximal humerus Am J Epdemiol 135 1992 477
83. N.H. Bell, J. Shary, and J. Stevens Demonstration that bone mass is greater in black than in white children J Bone Miner Res 6 1991 719
84. V. Gilsanz, T.F. Roe, and S. Mora Changes in vertebral bone density in black girls and white girls during childhood and puberty N Engl J Med 325 1991 1597
85. A. Sebastian, S.T. Harris, and J.H. Ottaway Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium carbonate N Engl J Med 330 1994 1776 1781
86. H.W. Daniell Osteoporosis of the slender smoker: vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity Arch Intern Med 136 1976 298
87. E. Seeman, L.J. Melton III, and W.M. O'Fallon Risk factors for spinal osteoporosis in men Am J Med 75 1983 977
88. J. Jensen, C. Christiansen, and P. Rodbro Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause N Engl J Med 313 1985 973
89. J.F. Aloia, S.H. Cohn, and A. Vaswani Risk factors for postmenopausal osteoporosis Am J Med 78 1985 95
90. H. Spencer, N. Rubio, and E. Rubio Chronic alcoholism: frequently overlooked cause of osteoporosis in men Am J Med 80 1986 393
91. N.A. Pocock, J.A. Eisman, and J.L. Hopper Genetic determinants of bone mass in the adult J Clin Invest 80 1987 706 710
92. J.C. Christian, P.-L. Yu, C.W. Slemenda, and C.C.J. Johnston Heretability of bone mass: a longitudinal study in aging male twins Am J Hum Genet 44 1989 429 433
93. G.S. Cooper, and D.M. Umbach Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis J Bone Miner Res 11 1996 1841 1849
94. B. Frame, and R.K. Nixon Bone-marrow mast cells in osteoporosis of aging N Engl J Med 279 1968 626
95. C. Ramos-Remus, J. Sibley, and A.S. Russell Steroids in rheumatoid arthritis: the honeymoon revisited J Rheumatol 19 1992 667
96. C. Nagant de Deuxchaisnes, J.P. Devogelaer, and W. Esselinckx The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and longitudinal study using single photon absorptiometry L.V. Avioli C. Gennari B. Imbimbo Glucocorticoid effects and their biological consequences 1982 Plenum Press New York 209
97. D.J. Baylink Glucocorticoid-induced osteoporosis [editorial] N Engl J Med 309 1983 306
98. C. Bressot, P.J. Meunier, and M.C. Chapuy Histomorphometric profile, pathophysiology, and reversibility of corticosteroid-induced osteoporosis Metab Bone Dis Relat Res 1 1979 303
99. T.J. Hahn, L.R. Halstead, and S.L. Teitelbau Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration J Clin Invest 64 1979 655
100. D.T. Villareal, R. Civitelli, and C. Genari Is there an effective treatment for glucocorticoid-induced osteoporosis? Calcif Tissue Int 49 1991 141
101. American College of Rheumatology Task Force on Osteoporosis Guidelines Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 39 1996 1791 1801
102. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis Ann Int Med 125 1996 961 968
103. J.A. Cauley, S.R. Cummings, and D.G. Seeley Effects of thiazide diuretic therapy on bone mass, fractures, and falls Ann Intern Med 118 1993 666
104. R.F.J.M. Laan, P.L.C.M. van Riel, and L.V.B.A. van de Putte Low dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study Ann Int Med 119 1993 963 968
105. J.R. Caldwell, and D.E. Furst The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis Semin Arthritis Rheum 21 1991 1
106. I. Joffe, and S. Epstein Osteoporosis associated with rheumatoid arthritis: pathogenesis and management Semin Arthritis Rheum 20 1991 256
107. B. Riis, K. Thomsen, and C. Christiansen Does calcium supplementation prevent post-menopausal bone loss? N Engl J Med 316 1987 173
108. S. Vedi, J.E. Compston, and A. Webb Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects Metab Bone Dis Relat Res 4 1982 231
109. P.M. Chavassieux, M.E. Arlot, and P.J. Meunier Intermethod variation in bone histomorphometry: comparison between manual and computerized methods applied to iliac bone biopsies Bone 6 1985 221
110. 85Sr kinetics J Bone Miner Res 2 1987 479
111. R.R. Recker, D.B. Kimmel, and A.M. Parfitt Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females J Bone Miner Res 3 1988 133
112. A.K. Taylor, S.A. Lueken, and C. Libanati Biochemical markers of bone turnover for the clinical assessment of bone metabolism Clin Rheum Dis 20 1994 589
113. P. Charles, C. Hasling, and L. Risteli Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level Calcif Tiss Int 51 1992 406
114. E.F. Eriksen, P. Charles, and F. Melsen Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry J Bone Miner Res 8 1993 127
115. A.C. Hassager, J. Risteli, and L. Risteli Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women J Bone Miner Res 7 1992 1307
116. K. Kushida, M. Takahashi, K. Kawana, and T. Inoue Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients J Clin Endocrinol Metab 80 1995 2447 2455
117. P.D. Delmas Biochemical markers of bone turnover J Bone Miner Res 8 Suppl 2 1993 S549 S555
118. L.S. Simon, S.M. Krane, and P.D. Wortman Serum levels of type I and type III procollagen fragments in Paget's disease of bone J Clin Endocrinol Metab 58 1984 110 120
119. S.P. Robins, D. Black, and C.R. Paterson Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases Eur J Clin Invest 21 1991 310
120. P. Delmas, E. Geneyts, and A. Bertholin Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease J Bone Miner Res 8 1993 643 648
121. K.I. Kivirikko Urinary excretion of hydroxyproline in health and disease Int Rev Connect Tissue Res 5 1970 93
122. P.H. Weiss, and L. Klein The quantitative relationship of urinary peptide hydroxyproline excretion to collagen degradation J Clin Invest 48 1969 1
123. A.M. Parfitt, L. Simon, and A.R. Villanueva Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen synthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphate J Bone Miner Res 2 1987 427
124. S. Epstein Serum and urinary markers of bone remodeling Endocr Rev 9 1988 437
125. P.D. Delmas Clinical use of biochemical markers of bone remodeling in osteoporosis Bone 13 1992 S17
126. D. Uebelhart, E. Gineyts, and M.-C. Chapuy Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease Bone Miner 8 1990 87
127. L.J. Beardsworth, D.R. Eyre, and I.R. Dickson Changes with age in the urinary excretion of Lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover J Bone Miner Res 5 1990 671
128. K. Panigrahi, P.D. Delmas, and F. Singer Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum Clin Chem 40 1994 822 828
129. D. Black, M. Marabani, and R.D. Sturrock Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis Ann Rheum Dis 48 1989 641
130. R.D. Harvey, K.C. McHardy, and I.W. Reid Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridium cross-links as specific urinary markers J Clin Endocrinol Metab 72 1991 1189
131. K. Reiser, R.J. McCormick, and R.B. Rucker Enzymatic and nonenzymatic crosslinking of collagen and elastin FASEB J 6 1992 2439
132. R.A. Greenwald Monitoring collagen degradation in patients with arthritis Arthritis Rheum 39 1996 1455 1465
133. S.R. Cummings, D. Black, and K. Ensrud Urine markers of bone resorption predict bone loss and fractures in older women: the study of osteoporotic fractures J Bone Miner Res 11 1996 S128
134. P. Ganero, E. Hausherr, and M.-C. Chapuy Markers of bone resorption predict fractures in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 1996 1531 1538
135. M. Singh, B.L. Riggs, and J.W. Beabout Femoral trabecular-pattern index for evaluation of spinal osteoporosis Ann Intern Med 77 1972 63
136. H.E. Meema, and S. Meema Cortical bone mineral density versus cortical thickness in diagnosis of osteoporosis: a roentgenologic-densitometric study J Am Geriatr Soc 17 1969 120
137. F.M. Hall, M.A. David, and D.T. Baran Bone mineral screening for osteoporosis N Engl J Med 316 1987 212
138. J.M. Pouilles, F. Tremollieres, and J.P. Louvet Sensitivity of dual-photon absorptiometry in spinal osteoporosis Calcif Tisse Int 43 1988 329
139. C. Bergot, A.-M. Laval-Jeantet, and F. Preteux Measurement of anisotropic vertebral trabecular bone loss during aging by quantitative image analysis Calcif Tissue Int 43 1988 143
140. T.L. Kelly, D.M. Slovik, and D.A. Schoenfeld Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine J Clin Endocrin Metab 67 1988 839
141. D.R. Baran, A.M. Kelly, and A. Karellas Ultrasound attenuation of the os calcis in women with osteoporosis and hip fractures Calcif Tissue Int 43 1988 138
142. C.R. Libanati, E.E. Schulz, and J.E. Shook Hip mineral density in females with a recent hip fracture J Clin Endocrinol Metab 74 1992 351
143. C.C. Johnston Jr, L.J. Melton III, R. Lindsay, and D.M. Eddy Clinical indications for bone mass measurements. A report from the Scientific Advisory Board of the National Osteoporosis Foundation J Bone Miner Res 4 Suppl 1989 2
144. C.W. Slemenda, S.L. Hill, and C. Longcope Predictors of bone mass in perimenopausal women Ann Intern Med 112 1990 96
145. F. Cosman, M.B. Schnitzer, and P.D. McCann Relationships between quantitative histological measurements and noninvasive assessments of bone mass Bone 13 1992 237
146. H.K. Genant, B. Ettinger, and C.E. Cann Osteoporosis: assessment by quantitative computed tomography Orthop Clin North Am 16 1985 557
147. P.D. Poss, J.W. Davis, J.M. Vogel, and R.D. Wasnich A critical review of bone mass and the risk of fractures in osteoporosis Calcif Tissue Int 46 1990 149 161
148. D.J. Sartoris, M. André, and C. Resnick Trabecular bone density in the proximal femur: quantitative CT assessment Radiology 160 1986 707
149. S. Gonnelli, C. Cepollaro, and D. Agnusdei Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women Osteoporos Int 5 1995 413 418
150. B.L. Riggs, H.W. Wahner, and W.L. Dunn Differential changes in bone mineral density of the appendicular and axial skeleton with aging J Clin Invest 67 1981 328
151. D.P.M. Symmons, A.M. Van Hemert, and J.P. Vanderbroncke A longitudinal study of back pain and radiological changes in the lumber spine of middle aged women. II. Radiographic findings Ann Rheum Dis 50 1991 162
152. P.J. Ryan, P. Evans, and T. Gibson Osteoporosis and chronic back pain: a study with single-photon emission computed tomography bone scintigraphy J Bone Miner Res 7 1992 1455
153. P.J. Ryan, P. Evans, and T. Gibson Chronic low back pain: comparison of bone SPECT with radiography and CT Radiology 182 1992 849
154. C. Christiansen Consensus development conference on osteoporosis Am J Med 91 5B 1991 1S
155. R.L. Prince, M. Smith, and I.M. Dick Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy N Engl J Med 325 1991 1190
156. B.D. Dawson-Hughes, G.E. Dallal, and E.A. Krall A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women N Engl J Med 323 1990 878
157. P.J.M. Elders, J.C. Netelenbos, and P. Lips Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age J Clin Endocrinol Metab 73 1991 533
158. I.R. Reid, R.W. Ames, and M.C. Evans Effect of calcium supplementation on bone loss in postmenopausal women N Engl J Med 328 1993 460
159. C. Christiansen Prevention and treatment of osteoporosis: a review of current modalities Bone 13 1992 S35
160. J.C. Gallagher, B.L. Riggs, and J. Eisman Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients J Clin Invest 64 1979 729
161. J.R. Bullamore, J.C. Gallagher, and R. Wilkinson Effect of age on calcium absorption Lancet 2 1970 535
162. C.C. Alevizaki, D.G. Ikkos, and P. Singhelakis Progressive decrease of true intestinal calcium absorption with age in normal man J Nucl Med 14 1973 760
163. J.F. Aloia, A. Vaswani, and J.K. Yeh Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss Ann Int Med 120 1994 97 103
164. 3 and calcium to prevent hip fractures in elderly women N Engl J Med 327 1992 1637 1642
165. M.W. Tilyard, G.F.S. Spears, J. Thomson, and S. Dovey Treatment of postmenopausal osteoporosis with calcitriol or calcium N Engl J Med 326 1992 357 362
166. P. Sambrook, J. Birmingham, and P. Kelley Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin N Engl J Med 328 1993 1747 1752
167. L.S. Richelson, W.W. Heinz, L.J. Melton, and B.L. Riggs Relative contributions of aging and estrogen deficiency to postmenopausal bone loss N Engl J Med 311 1984 1273 1275
168. J.C. Prior, Y.M. Vigna, and S.I. Barr Cyclic medroxyprogesterone treatment increases bone density Am J Med 96 1994 521
169. D.T. Felson, Y. Zhang, and M.T. Hannah The effect of postmenopausal estrogen therapy on bone density in elderly women N Engl J Med 329 1993 1141 1146
170. F.W. Lafferty, and M.E. Fiske Postmenopausal estrogen replacement: a long term cohort study Am J Med 97 1994 66
171. J.A. Cauley, D.G. Seely, and K. Ensrud Estrogen replacement therapy and fractures in older women Ann Int Med 122 1995 9 16
172. J.A. Grisso, J.L. Kelsey, and B.L. Strom Risk factors for hip fracture in black women N Engl J Med 330 1994 1555 1559
173. R. Lindsay, D.M. Hart, and C. Forrest Prevention of spinal osteoporosis in oophorectomised women Lancet 2 1980 1151
174. L.E. Nachtigall, R.H. Nachtigall, and R.D. Nachtigall Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis Obstet Gynecol 53 1979 277
175. N. Munk-Jensen, S.P. Nielsen, and P.B. Eriksen Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study BMJ 296 1988 1150
176. B. Ettinger, H.K. Genant, and C.E. Cann Long-term estrogen replacement therapy prevents bone loss and fractures Ann Intern Med 102 1985 319
177. D.P. Kiel, D.T. Felson, and J.J. Anderson Hip fracture and the use of estrogens in postmenopausal women N Engl J Med 317 1987 1169
178. T. Naessen, I. Persson, and H.-O. Adami Hormone replacement therapy and the risk for the first hip fracture. A prospective, population-based cohort study Ann Intern Med 113 1990 95
179. A. Paganini-Hill, R.K. Ross, and V.R. Gerkins Menopausal estrogen therapy and hip fractures Ann Intern Med 95 1981 28
180. N.S. Weiss, C.L. Ure, and J.H. Ballard Decreased risks of fractures of the hip and lower forearm with postmenopausal use of estrogen N Engl J Med 303 1980 1195
181. E.G. Lufkin, H.W. Wahner, and W.M. O'Fallon Treatment of postmenopausal osteoporosis with transdermal estrogen Ann Intern Med 117 1992 1
182. S. Adami, R. Suppi, and F. Bertoldo Transdermal estradiol in the treatment of postmenopausal bone loss Bone Min 7 1989 79
183. R. Lindsay, D.M. Hart, and D.M. Clark The minimum effective dose of estrogen for prevention of postmenopausal bone loss Obstet Gynecol 63 1984 759
184. B. Ettinger, H.K. Genant, and C.E. Cann Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium Ann Intern Med 106 1987 40
185. M.I. Whitehead, P.T. Townsend, and J. Pryse-Davies Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium N Engl J Med 304 1981 1599
186. C. Christiansen, and B.J. Riis 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women J Clin Endocrinol Metab 71 1990 836
187. D. Grady, S.M. Rubin, and D.B. Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016
188. K.K. Steinberg, S.B. Thacker, and J. Smith A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer JAMA 1 1991 265
189. G.A. Colditz, M.J. Stampfer, and W.C. Willett Prospective study of estrogen replacement therapy and risk in breast cancer in postmenopausal women JAMA 264 1990 2648
190. L. Berkvist, H.-O. Adami, and I. Persson The risk of breast cancer after estrogen and estrogen-progestin replacement N Engl J Med 321 1989 293
191. B.E. Henderson, R.K. Ross, and R.A. Lobo Re-evaluating the role of progestogen therapy after the menopause Fertil Steril 49 Suppl 5 1988 9S
192. D.L. Schneider, E.L. Barrett-Connor, and D.J. Morton Thyroid hormone use and bone mineral density in elderly women JAMA 271 1994 1245 1249
193. M. Srivastava, and C. Deal Osteoporosis in elderly: prevention and treatment Clin Geriatr Med 18 3 2002 529 555
194. L. Montemurro, G. Schiraldi, and P. Fraiolo Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients Calcif Tissue Int 49 1991 71 76
195. G.F. Mazzuoli, M. Passeri, and C. Gennari Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study Calcif Tissue Int 38 1986 3
196. C. Gennari, S.M. Chierichetti, and S. Bigazzi Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis Curr Ther Res 38 1985 455
197. I. MacIntyre, B.I. Whitehead, and L.M. Banks Calcitonin for prevention of postmenopausal bone loss Lancet 1 1988 900
198. K. Overgaard Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose response study Calcific Tissue Int 55 1994 82 86
199. K. Overgaard, B.J. Riis, C. Christinasen, and M.A. Hansen Effect of salcotonin given intranasally on early postmenopausal bone loss Br J Med 299 1989 477 479
200. K. Overgaard, M.A. Hansen, and S.B. Jensen Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis BMJ 305 1992 556
201. K. Overgaard, M.A. Hansen, and C. Christiansen Effect of intranasal calcitonin on bone mass and fracture rates in elderly women. A dose-response study [abstract] J Bone Miner Res 7 Suppl 1 1992 S117
202. C. Gennari, D. Agnusdei, and M. Montagnani An effective regimen of intranasal calcitonin in early postmenopausal bone loss Calcif Tissue Int 50 1992 381
203. K. Overgaard, B.J. Riis, and C. Christiansen Effect of salcatonin given intranasally on early postmenopausal bone loss BMJ 299 1989 477
204. J.Y. Reginster Effect of calcitonin on bone mass and fracture rates Am J Med 91 Suppl 5B 1991 19S
205. J.Y. Reginster, A. Albert, and M.P. Lecart One-year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin Lancet 2 1987 1481
206. K. Overgaard, M.A. Hansen, and C. Christiansen Effect of intranasal calcitonin on bone mass and bone turnover in early postmenopausal women [abstract] J Bone Miner Res 7 Suppl 1 1992 S140
207. R. Civitelli, S. Gonnelli, and F. Zachei Bone turnover in postmenopausal osteoporosis. Effect of calcitonin therapy J Clin Invest 82 1988 1268 1274
208. G.P. Lyritis, S. Tsakalabos, and B. Magiasis Analgesic effect of salmon calcitonin on osteoporotic vertebral fractures. Double-blind, placebo-controlled study Calcif Tissue Int 49 1991 369 372
209. N.B. Watts, S.T. Harris, and H.K. Genant Intermittent cyclical etidronate treatment of postmenopausal osteoporosis N Engl J Med 323 1990 73
210. A. Struys, A.A. Snelden, and H. Mulder Cyclic etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid induced osteoporosis Am J Med 99 1995 235 242
211. S.T. Harris, N.B. Watts, and R.D. Jackson Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy Am J Med 95 1993 557
212. T. Storm, G. Thamsborg, and T. Steiniche Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N Engl J Med 322 1990 1265 1271
213. S.E. Papapoulos, S.O. Landman, and O.L.M. Bijvoet The use of bisphosphonates in the treatment of osteoporosis Bone 13 Suppl 1 1992 S41
214. G. Seedor, H.A. Quartuccio, and D.D. Thompson The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats J Bone Miner Res 6 1991 339
215. U.A. Liberman, S.R. Weiss, and J. Broll Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1995 1437 1443
216. A.A. Licata Bisphosphonate therapy Am J Med Sci 313 1997 1
217. S.B. Cohen An update on bisphosphonates Curr Rheumatol Rep 6 2004 59 65
218. D.M. Black, S.R. Cummings, and D.B. Karpf Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535 1541
219. P. Geusens, J. Nijs, and G. Van der Perre Longitudinal effect on tiludronate on bone mineral density, resonant frequency and strength in monkeys J Bone Miner Res 7 1992 599
220. J.Y. Reginster, R. Deroisy, and D. Denis Prevention of postmenopausal bone loss by tiludronate Lancet 2 1989 1469
221. B.L. Riggs, D.J. Baylink, and M. Kleerekoper Incidence of hip fractures in osteoporotic women treated with sodium fluoride J Bone Miner Res 2 1987 123
222. B.L. Riggs, S.F. Hodgson, and W.M. O'Fallon Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis N Engl J Med 322 1990 802
223. C.Y.C. Pak, K. Sakhaee, and B. Adams-Huet Treatment of postmenopausal osteoporosis with slow-release sodium fluoride Ann Int Med 123 1995 401 408
224. J. Reeve, P.J. Meunier, and J.A. Parsons Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial BMJ 280 1980 1340
225. J. Reeve, J.N. Bradbeer, and M. Arlot hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses Osteoporos Int 1 1991 162
226. D.M. Slovik, R.M. Neer, and J.T. Potts Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients J Clin Invest 68 1981 1261
227. R. Neer, D. Slovik, and M. Daly Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol C. Chritstiansen K. Overgaard Osteoporosis 1990: Proceedings of the Third International Symposium on Osteoporosis 1990 Osteopress Aps Copenhagen 1314
228. R.M. Neer, D.M. Slovik, and S. Doppelt The use of parathyroid hormone plus 1,25- dihydroxyvitamin D to increase trabecular bone in osteoporotic men and postmenopausal women C. Chritstiansen K. Overgaard Osteoporosis 1990: Proceedings of the Third International Symposium on Osteoporosis 1990 Osteopress Aps Copenhagen 829
229. J.S. Finkelstein, A. Klibanski, and E.H. Schaefer Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency N Engl J Med 331 1994 1618 1623
230. M. Horwitz, A. Stewart, and S.L. Greenspan Sequential parathyroid hormone/alendronate therapy for osteoporosis-robbing Peter to pay Paul? J Clin Endocrinol Metab 85 2000 2129 2134
231. K.T. Brixen, P.M. Christensen, C. Ejersted, and B.L. Langdahl Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis Basic Clin Pharmacol Toxicol 94 2004 260 270
232. D. Conn New ways with old bones. Osteoporosis researchers look for drugs to replace hormone replacement therapy Lancet 363 2004 786 787
233. C.H. Chestnut III, J.L. Ivey, and H.E. Gruber Stanazol in the postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action Metabolism 32 1983 571 580
234. C. Hassager, B.J. Riis, J. Podenphat, and C. Chrisitnasen Nadrolone decanoate treatment of postmenopausal osteoporosis for 2 years and effects of withdrawal Maturitas 11 1989 305 317
235. P.J. Meunier, C. Roux, and E. Seeman The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468
236. Compston J. Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis. Osteoporosis International; published online October 12, 2004